Abstract
Overview
Introduction
The HIV market generated $7.4 billion of sales in 2005 and experienced a CAGR
of 13.3% from 2001-2005, making it one of the fastest growing infectious
diseases sub sectors. Despite the antiretroviral market' s relative immaturity,
many older flagship products such as Combivir are expected to lose patent
protection before 2015.
Scope
- In-depth analysis of the current HIV market across the major Western
markets (US, France, Germany, Italy, Spain, UK)
- Thorough assessment of underlying commercial and clinical influencing
factors shaping the antiretroviral market
- Detailed sales forecasts for the three major antiretroviral classes,
molecules and brands in each of the six major markets
- Case study analysis of the competitive environment and critical success
factors in the Protease Inhibitor class
Report Highlights
By 2015 the global antibacterial market is forecast to be valued at more than
$10 billion with a modest CAGR of 4.1%. The main contributor to growth will be
the new drug classes such as integrase- and entry inhibitors.
Since the advent of HAART, HIV has turned into a chronic disease with an
average life expectancy similar to that of Type 2 diabetes, emphasizing the
importance of side effect profiles associated with long-term use.
The launch of several new products from new classes such as integrase
inhibitors, CCR5 inhibitors from 2007, and recently launched PIs, will cause
the salvage market to decline. Despite proven synergy between Fuzeon and the
new drugs, use of the former is predicted to decline.
Reasons to Purchase
- Understand the constantly evolving market dynamics of antiretroviral (ARV)
drugs
- Explore the impact of pending patent expiries and generic incursion on the
ARV market, including product-specific case studies
- Obtain full global, country, class and product-specific forecasts of
currently marketed and pipeline ARVs from 2005 to 2015.
| 
View Cart
